Genmab says Phase 3 EPCORE DLBCL-2 trial shows epcoritamab plus R-CHOP cuts progression or death risk 51%
ABBV•Genmab and AbbVie reported positive topline Phase 3 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL, with the combination cutting the risk of progression or death by 51%.
1. Trial results
The Phase 3 EPCORE DLBCL-2 trial met its main goal, showing a delay in disease worsening versus R-CHOP alone in higher-risk patients. The safety profile was broadly consistent with known effects of the regimen.
2. Next steps
The companies plan to submit the results for presentation at a future medical meeting and engage regulators globally.
